Chemotherapy News and Research

Latest Chemotherapy News and Research

John Muir Health earns Network Cancer Program accreditation

John Muir Health’s Walnut Creek and Concord campuses have earned a three-year accreditation with commendation as a Network Cancer Program (NCP) from the American College of Surgeons Commission on Cancer (CoC), a consortium of professional organizations dedicated to improving survival and quality of life for cancer patients. John Muir Health is one of only two hospitals in California and the only one in the San Francisco Bay Area to receive the recognition.

24 Oct 2009

Health care changes forcing companies to adapt, could cost doctors

"Although thousands of doctors are converting their offices to electronic health records, a change the federal government supports with $19 billion in grants, there is a major catch — the government is still working on establishing a standard for e-records," the Las Vegas Sun reports. "Doctors who buy a software program could lose hundreds of thousands, if not millions of dollars, if their systems aren't compatible with the future government standard."

24 Oct 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

Exposing pregnant women to chemotherapy does not affect the foetus

Professor Frederic Amant of the Katholieke Universiteit Leuven (K.U.Leuven) directs research into the treatment of cancer in pregnant women and the consequences of such treatment on foetal development. In her PhD dissertation on chemotherapy during pregnancy, Kristel Van Calsteren presents new scientific discoveries.

23 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Aethlon Medical establishes ESI as a wholly owned subsidiary

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company.

23 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled.

21 Oct 2009

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement. The CI Index as a whole trades for 10% of estimated future revenues.

21 Oct 2009

Palmerolide A: Real hope for cancer treatment

A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

21 Oct 2009

STR genotyping and p57 immunohistochemistry used to distinguish hydatidiform moles

Researchers from The Johns Hopkins Medical Institutions have used short tandem repeat (STR) genotyping and p57 immunohistochemistry to distinguish hydatidiform moles.

21 Oct 2009

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today reported its third quarter 2009 results.

20 Oct 2009

A.P. Pharma to raise funds through placement

A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.

20 Oct 2009

NCCN Guidelines for Acute Myeloid Leukemia updated

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia, a cancer that starts inside the bone marrow and the most common acute leukemia affecting adults.

20 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

John Muir Health earns Network Cancer Program accreditation

Health care changes forcing companies to adapt, could cost doctors

Seattle Genetics reports its third-quarter financial results

Exposing pregnant women to chemotherapy does not affect the foetus

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Aethlon Medical establishes ESI as a wholly owned subsidiary

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Celgene announces fiscal 2009 third-quarter results

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

Palmerolide A: Real hope for cancer treatment

STR genotyping and p57 immunohistochemistry used to distinguish hydatidiform moles

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

A.P. Pharma to raise funds through placement

NCCN Guidelines for Acute Myeloid Leukemia updated

Cancer Research - Second Edition eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in